ClinicalTrials.gg
Sign In
Status unknownNCT05090930Updated Oct 25, 2021

Innovative Technologies for the Treatment of Pulmonary and Heart Failure

An interventional study of HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection and CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber in Cardiogenic Shock, Ventricular Arrythmia and Cardiac Arrest With Successful Resuscitation, sponsored by National Research Center for Cardiac Surgery, Kazakhstan. Status unknown at 1 site in Kazakhstan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-10-25.

Sponsored by National Research Center for Cardiac Surgery, Kazakhstan · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2021, registered Sep 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of the program. Formulation of new treatments for heart and pulmonary failure through using organ-replacing technologies.

Formulation of a clinical protocol and implementation of treatment methods into clinical practice heart and pulmonary failure using organ-replacing technologies.

New methods were created for rehabilitating the function of affected organs after implantation of the LVAD, a total artificial heart, an extracorporeal life-sustaining system will be of great importance, both for Kazakhstan and for states with similar problems of donor organ deficiency, will also improve the effectiveness of surgical treatment and reduce the level of complications and mortality of patients on the extracorporeal life-sustaining system and septic patients.

Read the detailed description

Objectives of the program. Task 1. Assessment of the results of the use of extracorporeal life support systems in the treatment of pulmonary and/or heart failure.

Subtask 1.1. Assessment of the restoration of organ function during extracorporeal life support systems using extracorporeal hemocorrection.

Subtask 1.2. Assessment of the normalization of the body's immune response and restoration of organ function during extracorporeal life support systems using an extracorporeal cytokine adsorber.

Task 2. Studying the restoration of organ function during implantation of the left ventricular assist device as an organ-replacing aid in heart failure.

Subtask 2.1. Assessment of the restoration of organ function during implantation of the left ventricular assist device with the use of extracorporeal hemocorrection.

Subtask 2.2. Assessment of the normalization of the body's immune response and restoration of organ function upon implantation of the left ventricular assist device using an extracorporeal cytokine adsorber.

Task 3. Studying the restoration of organ function during the implantation of the total artificial heart as an organ-replacing aid in case of heart failure.

Task 3.1. Assessment of normalization of organ function restoration during implantation of the total artificial heart with the use of extracorporeal hemocorrection.

Task 4. Studying the restoration of organ function during operations in conditions of the long-term cardiopulmonary bypass.

Task 4.1. Assessment of the restoration of organ function during operations with long-term cardiopulmonary bypass, hypothermia, and circulatory arrest, with the use of extra corporeal hemocorrection.

Task 4.2. Assessment of the restoration of organ function during operations with long-term cardiopulmonary bypass, hypothermia, and circulatory arrest using an extracorporeal cytokine adsorber.

Task 5. Improvement of the method of implantation of organ-replacing technologies to reduce complications in the treatment of heart and pulmonary failure.

Study design. Study type: interventional (clinical study) Set of participants: 100 participants Distribution: randomized Interventional model: parallel Masking: no Primary Goal: Treatment

02

Conditions studied

  • Cardiogenic Shock
  • Ventricular Arrythmia
  • Cardiac Arrest With Successful Resuscitation
  • Sepsis
  • Multiple Organ Failure
  • Pulmonary Failure
  • Decompensated Heart Failure
  • Acute Heart Failure

Keywords

  • Anesthesiology
  • Cardiothoracic surgery
  • Nephrology
  • Perfusion
  • Efferentology
03

In context

Shock, Cardiogenic

296 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

This study's planned enrollment of 100 is above the median of 80 across 133 interventional studies indexed under Shock, Cardiogenic.

Browse Shock, Cardiogenic studies →

Lead sponsor

National Research Center for Cardiac Surgery, Kazakhstan is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients on an extracorporeal life support system with heart failure:

  • Implantation of intravenous ECMO
  • Hemodynamic support with vasopressors and/or tonics;
  • Procalcitonin level ≥ 1 ng/ml;
  • Invasive hemodynamic monitoring;
  • Written .

Patients on an extracorporeal life support system with pulmonary failure:

  • IV ECMO implantation
  • High levels of venous and arterial CO2 (CO2> 50 mmHg),
  • Low paO2, SvO2, SpO2.
  • Invasive hemodynamic monitoring;

  • Written informed consent.

    -Patients with left ventricular assistive device implantation:

  • LVAD implantation
  • Biventricular heart failure IV
  • INTERMACS I-III
  • Hemodynamic support with vasopressors and/or tonics;
  • Procalcitonin level ≥ 0.1 ng/ml;
  • Invasive hemodynamic monitoring;

  • Written informed consent.

    -Patients in operations with prolonged artificial circulation, hypothermia and circulatory arrest:

  • Hemodynamic support with vasopressors and/or tonics;
  • Bypass duration> 120 minutes
  • Hypothermia ≤ 25 0С
  • Circulatory arrest
  • Procalcitonin level ≥ 1 ng/ml;
  • Invasive hemodynamic monitoring;
  • Written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Patients on an extracorporeal life support system with heart failure:

    • Age less than 18 years old
    • Terminal hepatic or renal failure just before the procedure
    • Patient's written refusal to participate in the study

  • Patients on an extracorporeal life support system with pulmonary failure:

    • Age less than 18 years old
    • Terminal hepatic or renal failure just before the procedure
    • Patient's written refusal to participate in the study

  • Patients with left ventricular assistive device implantation:

    • Age less than 18 years old
    • Acute hepatic or renal failure just before the procedure
    • Patient's written refusal to participate in the study

  • Patients in operations with prolonged artificial circulation, hypothermia and circulatory arrest:

    • Age less than 18 years old
    • Terminal hepatic or renal failure just before the procedure
    • Patient's written refusal to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Intervention team (1/1 group)

    An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for heart failure... (10 patients)

    Device: HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection

  • Active comparator
    Intervention team (1/2 group)

    An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for pulmonary failure (10 patients).

    Device: HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection

  • Active comparator
    Intervention team (1/3 group)

    An extracorporeal hemoperfusion device will be installed in patients before/during the implantation of a left ventricular accessory (5 patients).

    Device: HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection

  • Active comparator
    Intervention team (1/4 group)

    An extracorporeal hemoperfusion device will be installed in patients during operations with prolonged artificial circulation, hypothermia, and circulatory arrest. (25 patients).

    Device: HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection

  • Active comparator
    Intervention team (2/1 groups)

    An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for heart failure. (10 patients)

    Device: CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber

  • Active comparator
    Intervention team (2/2 groups)

    An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for pulmonary failure. (10 patients)

    Device: CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber

  • Active comparator
    Intervention team (2/3 groups)

    An extracorporeal hemoperfusion device will be installed in patients before/during the implantation of a left ventricular accessory (5 patients)

    Device: CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber

  • Active comparator
    Intervention team (2/4 groups)

    An extracorporeal hemoperfusion device will be installed in patients during operations with prolonged artificial circulation, hypothermia, and circulatory arrest. (25 patients)

    Device: CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber

Interventions

  • DeviceHA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection

    HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection, which is based on the removal of cytokines from whole blood by sorption on a special hemoadsorbent due to the peculiarities of its porous structure and inner surface, which is indicated in conditions where cytokine levels are extremely elevated

  • DeviceCytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber

    CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber is a biocompatible polymer with high adsorption capacity, which is indicated in conditions where cytokine levels are extremely elevated

06

What researchers measure

Primary outcomes

  1. Extracorporeal life support system with pulmonary and / or heart failure: Cytokine response

    The level of pro- and anti-inflammatory cytokines (IL-1, IL-6, IL-8, IL-10, tumor alpha-factor) before the start, 2 hours after the start of ECMO support, when ECMO is turned off, 24 hours after ECMO is turned off.

    Time frame: 24-48 hours

  2. Extracorporeal life support system with pulmonary and / or heart failure: SOFA-Score

    Sequential Organ Failure Assessment Score at 24, 48, 72 h (values from 6 to 24, where the higher values explain higher disease severity)

    Time frame: 24, 48, 72 hours

  3. Extracorporeal life support system with pulmonary and / or heart failure

    Doses of vasopressors and / or inotropes (µg / h / kg bodyweight)

    Time frame: Time: first 72 hours

  4. Patients with left ventricular assist device implantation: Difference of Cytokine response

    Level of pro- and anti-inflammatory cytokines (IL-1, IL-6, IL-8, IL-10, tumor necrosis factor-alfa, procalcitonin)

    Time frame: 24-48 hours

  5. Patients with left ventricular assist device implantation:vasopressors and / or inotropes

    Doses of vasopressors and / or inotropes (µg / h / kg bodyweight)

    Time frame: first 72 hours

  6. Patients with left ventricular assist device implantation:Renal function

    creatinine level

    Time frame: first 72 hours

  7. Patients with left ventricular assist device implantation:Lactate level

    Lactate level

    Time frame: first 72 hours

  8. For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Difference of Cytokine response

    Level of pro- and anti-inflammatory cytokines (IL-1, IL-6, IL-8, IL-10, tumor necrosis factor-alfa, procalcitonin, C-reactive protein)

    Time frame: 24-48 hours

  9. For operations with prolonged artificial circulation, hypothermia and circulatory arrest: SOFA-Score

    Sequential Organ Failure Assessment Score at 24, 48, 72 h (values from 6 to 24, where the higher values explain higher disease severity)

    Time frame: 24, 48, 72 hours

  10. Extracorporeal life support system with pulmonary and / or heart failure:Difference of mean arterial pressure

    Comparison of mean arterial pressure at 24, 48, 72 hours between between two interventions (CytoSorb and Jafron)

    Time frame: 24, 48, 72 hours

  11. Extracorporeal life support system with pulmonary and / or heart failure: Difference of CVP

    Comparison of CVP at 24, 48, 72 hours between between two interventions (CytoSorb and Jafron)

    Time frame: 24, 48, 72 hours

  12. Extracorporeal life support system with pulmonary and / or heart failure: Serum lactate

    Level of serum lactate at 24, 48, 72 h

    Time frame: 24, 48, 72 hours

  13. Extracorporeal life support system with pulmonary and / or heart failure:Days on ventilator, vasopressor and renal replacement therapy

    Total days on ventilator, vasopressor and renal replacement therapy within 30 days post-surgery will be assessed

    Time frame: until day 30 post-surgery

  14. For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Difference of mean arterial pressure

    Comparison of mean arterial pressure at 24, 48, 72 hours between between two interventions (CytoSorb and Jafron)

    Time frame: 24, 48, 72 hours

  15. For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Difference of CVP

    Comparison of mean arterial pressure at 24, 48, 72 hours between between two interventions (CytoSorb and Jafron)

    Time frame: 24, 48, 72 hours

  16. For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Level of Serum lactate

    Comparison of mean arterial pressure at 24, 48, 72 hours between between two interventions (CytoSorb and Jafron)

    Time frame: 24, 48, 72 hours

Secondary outcomes

  1. Extracorporeal life support system with pulmonary and / or heart failure:The level of C-reactive protein (CRP)

    The level of C-reactive protein (CRP) before the start of ECMO, 2 hours after the implantation of ECMO, during ECMO, 24 hours after ECMO explantation.

    Time frame: 24-48 hours

  2. Extracorporeal life support system with pulmonary and / or heart failure: Level of leukocyte

    Level of leukocyte cells in the bloodstream at 24, 48 hours

    Time frame: 24-48 hours

  3. Extracorporeal life support system with pulmonary and / or heart failure:Application and dosage of vasopressors

    Incidence of application and level of dosage of vasopressors on days 2 and 3 after surgery

    Time frame: first 48 hours

  4. Patients with left ventricular assist device implantation: The level of C-reactive protein (CRP)

    The level of C-reactive protein (CRP) before the start of the operation, 2 hours after the start of the operation, when the operation is turned off, 24 hours after the shutdown of the operation

    Time frame: 24-48 hours

  5. Patients with left ventricular assist device implantation: Application and dosage of vasopressors

    Incidence of application and level of dosage of vasopressors on days 2 and 3 after surgery

    Time frame: first 48 hours

  6. For operations with prolonged artificial circulation, hypothermia and circulatory arrest: The level of C-reactive protein (CRP)

    The level of C-reactive protein (CRP) before the cardiopulmonary bypass 2 hours after the cardiopulmonary bypass, when the cardiopulmonary bypass is turned off, 24 hours after the cardiopulmonary bypass.

    Time frame: 24-48 hours

  7. For operations with prolonged artificial circulation, hypothermia and circulatory arrest:Leukocyte function

    Leukocyte function: heterogeneity of the population of leukocyte cells in the bloodstream

    Time frame: first 48 hours

  8. For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Application and dosage of vasopressors

    Incidence of application and level of dosage of vasopressors on days 2 and 3 after surgery

    Time frame: first 48 hours

  9. Extracorporeal life support system with pulmonary and / or heart failure:The level of leukocytes

    The level of leukocytes before the start of ECMO, 2 hours after the implantation of ECMO, during ECMO, 24 hours after ECMO explantation

    Time frame: 24-48 hours

  10. Extracorporeal life support system with pulmonary and / or heart failure:The level of procalcitonin

    The level of procalcitonin before the start of ECMO, 2 hours after the implantation of ECMO, during ECMO, 24 hours after ECMO explantation.

    Time frame: 24-48 hours

  11. Extracorporeal life support system with pulmonary and / or heart failure:Application and dosage of inotropes

    Incidence of application and level of dosage of inotropes on days 2 and 3 after surgery

    Time frame: first 48 hours

  12. Patients with left ventricular assist device implantation: The level of leukocytes

    The level of leukocytes before the start of the operation, 2 hours after the start of the operation, when the operation is turned off, 24 hours after the shutdown of the operation

    Time frame: 24-48 hours

  13. Patients with left ventricular assist device implantation: The level of procalcitonin

    The level of procalcitonin before the start of the operation, 2 hours after the start of the operation, when the operation is turned off, 24 hours after the shutdown of the operation

    Time frame: 24-48 hours

  14. Patients with left ventricular assist device implantation: Application and dosage of inotropes

    Incidence of application and level of dosage of inotropes on days 2 and 3 after surgery

    Time frame: first 48 hours

  15. For operations with prolonged cardio pulmonary bypass, hypothermia and circulatory arrest: The level of leukocytes

    The level of leukocytes before the cardiopulmonary bypass 2 hours after the cardiopulmonary bypass, when the cardiopulmonary bypass is turned off, 24 hours after the cardiopulmonary bypass.

    Time frame: 24-48 hours

  16. For operations with prolonged cardiopulmonary bypass, hypothermia, and circulatory arrest: The level of procalcitonin

    The level of procalcitonin before the cardiopulmonary bypass 2 hours after the cardiopulmonary bypass, when the cardiopulmonary bypass is turned off, 24 hours after the cardiopulmonary bypass.

    Time frame: 24-48 hours

  17. For operations with prolonged cardiopulmonary bypass, hypothermia, and circulatory arrest: Application and dosage of inotropes

    Incidence of application and level of dosage of inotropes on days 2 and 3 after surgery

    Time frame: first 48 hours

Other outcomes

  1. Length of stay

    Length of stay in the intensive care unit

    Time frame: first 48 hours

  2. Length of hospital stay

    Length of hospital stay

    Time frame: up to 1 month

  3. 30 day survival rate.

    30 day survival rate.

    Time frame: 30 day

07

Study locations

1 of 1 sites recruiting
  • National Research Center For Cardiac Surgery
    Astana, 010000, Kazakhstan
    Recruiting
08

References and documents

Publications

  • Starling RC. Improved quantity and quality of life: a winning combination to treat advanced heart failure. J Am Coll Cardiol. 2010 Apr 27;55(17):1835-6. doi: 10.1016/j.jacc.2010.03.010. No abstract available. PubMed 20413034 ↗
  • Maciver J, Ross HJ. Quality of life and left ventricular assist device support. Circulation. 2012 Aug 14;126(7):866-74. doi: 10.1161/CIRCULATIONAHA.111.040279. No abstract available. PubMed 22891167 ↗
  • Tozzi P, Hullin R. Mechanical circulatory support for destination therapy. Swiss Med Wkly. 2016 Mar 5;146:w14267. doi: 10.4414/smw.2016.14267. eCollection 2016. PubMed 26945160 ↗
  • Paolone S. Extracorporeal Membrane Oxygenation (ECMO) for Lung Injury in Severe Acute Respiratory Distress Syndrome (ARDS): Review of the Literature. Clin Nurs Res. 2017 Dec;26(6):747-762. doi: 10.1177/1054773816677808. Epub 2016 Nov 11. PubMed 27836935 ↗
  • Abrams D, Garan AR, Abdelbary A, Bacchetta M, Bartlett RH, Beck J, Belohlavek J, Chen YS, Fan E, Ferguson ND, Fowles JA, Fraser J, Gong M, Hassan IF, Hodgson C, Hou X, Hryniewicz K, Ichiba S, Jakobleff WA, Lorusso R, MacLaren G, McGuinness S, Mueller T, Park PK, Peek G, Pellegrino V, Price S, Rosenzweig EB, Sakamoto T, Salazar L, Schmidt M, Slutsky AS, Spaulding C, Takayama H, Takeda K, Vuylsteke A, Combes A, Brodie D; International ECMO Network (ECMONet) and The Extracorporeal Life Support Organization (ELSO). Position paper for the organization of ECMO programs for cardiac failure in adults. Intensive Care Med. 2018 Jun;44(6):717-729. doi: 10.1007/s00134-018-5064-5. Epub 2018 Feb 15. PubMed 29450594 ↗
  • Hunt SA. Taking heart--cardiac transplantation past, present, and future. N Engl J Med. 2006 Jul 20;355(3):231-5. doi: 10.1056/NEJMp068048. No abstract available. Erratum In: N Engl J Med. 2006 Aug 31;355(9):967. PubMed 16855261 ↗
  • Hunt SA, Haddad F. The changing face of heart transplantation. J Am Coll Cardiol. 2008 Aug 19;52(8):587-98. doi: 10.1016/j.jacc.2008.05.020. PubMed 18702960 ↗
  • Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, Dobbels F, Goldfarb SB, Levvey BJ, Meiser B, Yusen RD, Stehlik J; International Society of Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report--2014; focus theme: retransplantation. J Heart Lung Transplant. 2014 Oct;33(10):996-1008. doi: 10.1016/j.healun.2014.08.003. Epub 2014 Aug 14. No abstract available. PubMed 25242124 ↗
  • Sogayar AM, Machado FR, Rea-Neto A, Dornas A, Grion CM, Lobo SM, Tura BR, Silva CL, Cal RG, Beer I, Michels V, Safi J, Kayath M, Silva E; Costs Study Group - Latin American Sepsis Institute. A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units. Pharmacoeconomics. 2008;26(5):425-34. doi: 10.2165/00019053-200826050-00006. PubMed 18429658 ↗
  • Khwannimit B, Bhurayanontachai R. The direct costs of intensive care management and risk factors for financial burden of patients with severe sepsis and septic shock. J Crit Care. 2015 Oct;30(5):929-34. doi: 10.1016/j.jcrc.2015.05.011. Epub 2015 May 20. PubMed 26051981 ↗
  • Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ, Kurosawa S, Stepien D, Valentine C, Remick DG. Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev. 2013 Jul;93(3):1247-88. doi: 10.1152/physrev.00037.2012. PubMed 23899564 ↗
  • Kwan A, Hubank M, Rashid A, Klein N, Peters MJ. Transcriptional instability during evolving sepsis may limit biomarker based risk stratification. PLoS One. 2013;8(3):e60501. doi: 10.1371/journal.pone.0060501. Epub 2013 Mar 27. PubMed 23544148 ↗
  • Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006 Feb 24;124(4):783-801. doi: 10.1016/j.cell.2006.02.015. PubMed 16497588 ↗
  • Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013 Dec;13(12):862-74. doi: 10.1038/nri3552. Epub 2013 Nov 15. PubMed 24232462 ↗
  • Venet F, Lukaszewicz AC, Payen D, Hotchkiss R, Monneret G. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr Opin Immunol. 2013 Aug;25(4):477-83. doi: 10.1016/j.coi.2013.05.006. Epub 2013 May 28. PubMed 23725873 ↗
  • Laszlo I, Trasy D, Molnar Z, Fazakas J. Sepsis: From Pathophysiology to Individualized Patient Care. J Immunol Res. 2015;2015:510436. doi: 10.1155/2015/510436. Epub 2015 Jul 15. PubMed 26258150 ↗
  • Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009 Jun 17;301(23):2445-52. doi: 10.1001/jama.2009.856. PubMed 19531784 ↗
  • Bellomo R, Baldwin I, Ronco C. Extracorporeal blood purification therapy for sepsis and systemic inflammation: its biological rationale. Contrib Nephrol. 2001;(132):367-74. doi: 10.1159/000060105. PubMed 11395904 ↗
  • Namas RA, Namas R, Lagoa C, Barclay D, Mi Q, Zamora R, Peng Z, Wen X, Fedorchak MV, Valenti IE, Federspiel WJ, Kellum JA, Vodovotz Y. Hemoadsorption reprograms inflammation in experimental gram-negative septic peritonitis: insights from in vivo and in silico studies. Mol Med. 2012 Dec 20;18(1):1366-74. doi: 10.2119/molmed.2012.00106. PubMed 22751621 ↗
  • Peng ZY, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med. 2008 May;36(5):1573-7. doi: 10.1097/CCM.0b013e318170b9a7. PubMed 18434884 ↗
  • Peng ZY, Wang HZ, Carter MJ, Dileo MV, Bishop JV, Zhou FH, Wen XY, Rimmele T, Singbartl K, Federspiel WJ, Clermont G, Kellum JA. Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney Int. 2012 Feb;81(4):363-9. doi: 10.1038/ki.2011.320. Epub 2011 Sep 14. PubMed 21918497 ↗
  • Kellum JA, Venkataraman R, Powner D, Elder M, Hergenroeder G, Carter M. Feasibility study of cytokine removal by hemoadsorption in brain-dead humans. Crit Care Med. 2008 Jan;36(1):268-72. doi: 10.1097/01.CCM.0000291646.34815.BB. PubMed 18090355 ↗
  • Friesecke S, Trager K, Schittek GA, Molnar Z, Bach F, Kogelmann K, Bogdanski R, Weyland A, Nierhaus A, Nestler F, Olboeter D, Tomescu D, Jacob D, Haake H, Grigoryev E, Nitsch M, Baumann A, Quintel M, Schott M, Kielstein JT, Meier-Hellmann A, Born F, Schumacher U, Singer M, Kellum J, Brunkhorst FM. International registry on the use of the CytoSorb(R) adsorber in ICU patients : Study protocol and preliminary results. Med Klin Intensivmed Notfmed. 2019 Nov;114(8):699-707. doi: 10.1007/s00063-017-0342-5. Epub 2017 Sep 4. PubMed 28871441 ↗
  • Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18. PubMed 28101605 ↗
  • Moreno R, Vincent JL, Matos R, Mendonca A, Cantraine F, Thijs L, Takala J, Sprung C, Antonelli M, Bruining H, Willatts S. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med. 1999 Jul;25(7):686-96. doi: 10.1007/s001340050931. PubMed 10470572 ↗
  • Hetz H, Berger R, Recknagel P, Steltzer H. Septic shock secondary to beta-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy. Int J Artif Organs. 2014 May;37(5):422-6. doi: 10.5301/ijao.5000315. Epub 2014 Apr 17. PubMed 24811308 ↗
  • Kogelmann K, Jarczak D, Scheller M, Druner M. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care. 2017 Mar 27;21(1):74. doi: 10.1186/s13054-017-1662-9. PubMed 28343448 ↗
  • David S, Thamm K, Schmidt BMW, Falk CS, Kielstein JT. Effect of extracorporeal cytokine removal on vascular barrier function in a septic shock patient. J Intensive Care. 2017 Jan 21;5:12. doi: 10.1186/s40560-017-0208-1. eCollection 2017. PubMed 28127437 ↗
  • Nemeth E, Kovacs E, Racz K, Soltesz A, Szigeti S, Kiss N, Csikos G, Koritsanszky KB, Berzsenyi V, Trembickij G, Fabry S, Prohaszka Z, Merkely B, Gal J. Impact of intraoperative cytokine adsorption on outcome of patients undergoing orthotopic heart transplantation-an observational study. Clin Transplant. 2018 Apr;32(4):e13211. doi: 10.1111/ctr.13211. Epub 2018 Feb 27. Erratum In: Clin Transplant. 2019 Jun;33(6):e13556. doi: 10.1111/ctr.13556.. Abstract corrected. PubMed 29377282 ↗
  • Trasy D, Tanczos K, Nemeth M, Hankovszky P, Lovas A, Mikor A, Laszlo I, Hajdu E, Osztroluczki A, Fazakas J, Molnar Z; EProK study group. Early procalcitonin kinetics and appropriateness of empirical antimicrobial therapy in critically ill patients: A prospective observational study. J Crit Care. 2016 Aug;34:50-5. doi: 10.1016/j.jcrc.2016.04.007. Epub 2016 Apr 13. PubMed 27288610 ↗
  • Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis. 2012 Jul;73(3):221-7. doi: 10.1016/j.diagmicrobio.2012.05.002. PubMed 22704255 ↗
  • Nylen ES, Whang KT, Snider RH Jr, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med. 1998 Jun;26(6):1001-6. doi: 10.1097/00003246-199806000-00015. PubMed 9635646 ↗
  • Schadler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, Marx G, Putensen C, Spies C, Jorres A, Quintel M, Engel C, Kellum JA, Kuhlmann MK. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial. PLoS One. 2017 Oct 30;12(10):e0187015. doi: 10.1371/journal.pone.0187015. eCollection 2017. PubMed 29084247 ↗
  • Trasy D, Molnar Z. Procalcitonin - Assisted Antibiotic Strategy in Sepsis. EJIFCC. 2017 May 1;28(2):104-113. eCollection 2017 May. PubMed 28757818 ↗
  • Tschaikowsky K, Sagner S, Lehnert N, Kaul M, Ritter J. Endothelin in septic patients: effects on cardiovascular and renal function and its relationship to proinflammatory cytokines. Crit Care Med. 2000 Jun;28(6):1854-60. doi: 10.1097/00003246-200006000-00028. PubMed 10890632 ↗
  • Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018 Mar 20;137(12):e67-e492. doi: 10.1161/CIR.0000000000000558. Epub 2018 Jan 31. No abstract available. Erratum In: Circulation. 2018 Mar 20;137(12):e493. doi: 10.1161/CIR.0000000000000573. PubMed 29386200 ↗
  • Rodriguez LE, Suarez EE, Loebe M, Bruckner BA. Ventricular assist devices (VAD) therapy: new technology, new hope? Methodist Debakey Cardiovasc J. 2013 Jan-Mar;9(1):32-7. doi: 10.14797/mdcj-9-1-32. PubMed 23519193 ↗
  • Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, Rogers JG, Naka Y, Mancini D, Miller LW. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007 Jul 31;116(5):497-505. doi: 10.1161/CIRCULATIONAHA.107.691972. Epub 2007 Jul 16. PubMed 17638928 ↗
  • Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, Morgan JA, Arabia F, Bauman ME, Buchholz HW, Deng M, Dickstein ML, El-Banayosy A, Elliot T, Goldstein DJ, Grady KL, Jones K, Hryniewicz K, John R, Kaan A, Kusne S, Loebe M, Massicotte MP, Moazami N, Mohacsi P, Mooney M, Nelson T, Pagani F, Perry W, Potapov EV, Eduardo Rame J, Russell SD, Sorensen EN, Sun B, Strueber M, Mangi AA, Petty MG, Rogers J; International Society for Heart and Lung Transplantation. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013 Feb;32(2):157-87. doi: 10.1016/j.healun.2012.09.013. No abstract available. PubMed 23352391 ↗
  • Hetzer R, Delmo Walter EM. Trends and outcomes in heart transplantation: the Berlin experience. HSR Proc Intensive Care Cardiovasc Anesth. 2013;5(2):76-80. PubMed 23888228 ↗
  • Chen YF, Tsai WC, Lin CC, Tsai LY, Lee CS, Huang CH, Pan PC, Chen ML. Effect of leukocyte depletion on endothelial cell activation and transendothelial migration of leukocytes during cardiopulmonary bypass. Ann Thorac Surg. 2004 Aug;78(2):634-42; discussion 642-3. doi: 10.1016/j.athoracsur.2004.02.091. PubMed 15276536 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Yes: There is a plan to make IPD and related data dictionaries available.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: from October 2021 year and will become available till December 2023 year.

Access criteria: The resulting patient data will be strictly confidential with ensuring privacy through strictly limited access to data, de-identification of data and destruction after the end of the study.

Data sharing details ↗ · heartcenter.kz

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Jul 2023, 30 months after the start.

Of 49 non-industry interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 30 months is below that.

Counting every sponsor, half of 53 studies reached it within 39 months; a quarter within 24 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2021
First posted
Oct 25, 2021
StartActual
Jan 1, 2021
Primary completionEst.
Jul 1, 2023
CompletionEst.
Dec 1, 2023
Last update
Oct 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05090930
Lead sponsor
National Research Center for Cardiac Surgery, Kazakhstan
Collaborators
Ministry of Education and Science, Republic of Kazakhstan
Responsible party
Yuriy Pya (Director for Surgery and Science, National Research Center for Cardiac Surgery, Kazakhstan) — Principal investigator
First posted
Oct 25, 2021
Start date
Jan 1, 2021
Primary completion
Jul 1, 2023 (estimated)
Completion
Dec 1, 2023 (estimated)
Last update
Oct 25, 2021

Study contacts

Yuri Pya, PhD, MD
Contact
rp.nrcsc@gmail.com
+77172272090
Timur Lesbekov, MD
Contact
lesbekovt@mail.ru
+77172703100
Yuri Pya, PhD, MD
principal investigator · National research Center for Cardiac Surgery JSC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Shock, Cardiogenic →

Other studies from this sponsor

National Research Center for Cardiac Surgery, Kazakhstan

Start the discussion